MBX Biosciences (MBX) Fundamental Analysis: Revenue, Earnings & Valuation

8.76 / 10

Outperform

Fundamentals are rated Outperform with an 8.8/10 score. Strengths include high interest coverage (35.1), strong PB‑ROE (1.67) and robust revenue growth (>130%). A concern is the elevated current‑liabilities ratio (97.3%). Overall, fundamentals appear excellent.

Analysis Checks(9/10)

Revenue-MV

Value-0.11

Score3/3

Weight30.89%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.42%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.52%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value97.32

Score0/3

Weight-13.05%

1M Return-4.96%

PB-ROE

Value1.67

Score3/3

Weight38.91%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.00

Score2/3

Weight-1.09%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.58%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.17%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.38%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight54.24%

1M Return11.61%

Is MBX undervalued or overvalued?

MBX scores 8.76/10 on fundamentals and holds a Discounted valuation at present. Backed by its -27.76% ROE, 0.00% net margin, -17.64 P/E ratio, 4.15 P/B ratio, and 59.11% earnings growth, these metrics solidify its Outperform investment rating.